



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Katsunari Tezuka et al. Art Unit : 1644
Serial No. : 09/830,548 Examiner : Jessica Roark, Ph.D.
Filed : June 12, 2001
Title : A PHARMACEUTICAL COMPOSITION FOR TREATING IMMUNE DISEASES

Commissioner for Patents
Washington, D.C. 20231

22
JM
4/3/03

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated March 6, 2003, applicants elect the invention of Group V, drawn to the embodiment of methods of preventing or treating graft versus host reaction by administering a protein substance that modulates signal transduction by AILIM. In response to the requirement for election of species, applicants elect an antibody that binds to AILIM. Claims 18-22 read on the elected species.

As detailed in paragraph 4 of the Restriction Requirement, upon allowance of linking claim 18, the restriction as to Groups V and VI shall be withdrawn and any claims depending from or otherwise including all of the limitations of the allowable linking claim will be entitled to examination in the present application.

RECEIVED

APR 03 2003

TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

March 26, 2003

Signature

Annette Mejia

Typed or Printed Name of Person Signing Certificate

Annette Mejia

Applicant : Katsunari Tezuka
Serial No. : 09/830,548
Filed : June 12, 2001
Page : 2

Attorney's Docket No.: 14539-005001 / JF-82US

Please apply any charges or credits to Deposit Account No. 06-1050, referencing
Attorney Docket No. 14539-005001.

Respectfully submitted,

Date: _____

March 26, 2003

Jack Brennan

Jack Brennan
Reg. No. 47,443

Fish & Richardson P.C.
45 Rockefeller Plaza, Suite 2800
New York, New York 10111
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

30140855.doc